{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Binks SNM"],"funding":["Petre Foundation","Epilepsy Research UK","Medical Research Council","NIHR Oxford Biomedical Research Centre","National Institute for Health Research (NIHR)","National Health and Medical Research Council","University of Sydney","National Institute for Health and Care Research","British Medical Association","Wellcome Trust","Royal Australasian College of Physicians","US-UK Fulbright Commission"],"pagination":["1053-1058"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11021603"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(4)"],"pubmed_abstract":["Patient-reported quality-of-life (QoL) and carer impacts are not reported after leucine-rich glioma-inactivated 1-antibody encephalitis (LGI1-Ab-E). From 60 patients, 85% (51 out of 60) showed one abnormal score across QoL assessments and 11 multimodal validated questionnaires. Compared to the premorbid state, QoL significantly deteriorated (p < 0.001) and, at a median of 41 months, fatigue was its most important predictor (p = 0.025). In total, 51% (26 out of 51) of carers reported significant burden. An abbreviated five-item battery explained most variance in QoL. Wide-ranging impacts post-LGI1-Ab-E include decreased QoL and high caregiver strain. We identify a rapid method to capture QoL in routine clinic or clinical trial settings."],"journal":["Annals of clinical and translational neurology"],"pubmed_title":["Fatigue predicts quality of life after leucine-rich glioma-inactivated 1-antibody encephalitis."],"pmcid":["PMC11021603"],"funding_grant_id":["MR/V007173/1","CL-2022-13-007","Margaret Temple 2017","206330/Z/17/Z","P1201","MR/X022013/1","Vera Down grant 2013","104079/Z/14/Z","GNT2008339"],"pubmed_authors":["Michael S","Nissen MS","Jacob S","Okai D","Binks SNM","Handel AE","Irani SR","Coebergh J","Blaabjerg M","Maddison P","Ramanathan S","Leite MI","Easton A","Husain M","Veldsman M"],"additional_accession":[]},"is_claimable":false,"name":"Fatigue predicts quality of life after leucine-rich glioma-inactivated 1-antibody encephalitis.","description":"Patient-reported quality-of-life (QoL) and carer impacts are not reported after leucine-rich glioma-inactivated 1-antibody encephalitis (LGI1-Ab-E). From 60 patients, 85% (51 out of 60) showed one abnormal score across QoL assessments and 11 multimodal validated questionnaires. Compared to the premorbid state, QoL significantly deteriorated (p < 0.001) and, at a median of 41 months, fatigue was its most important predictor (p = 0.025). In total, 51% (26 out of 51) of carers reported significant burden. An abbreviated five-item battery explained most variance in QoL. Wide-ranging impacts post-LGI1-Ab-E include decreased QoL and high caregiver strain. We identify a rapid method to capture QoL in routine clinic or clinical trial settings.","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Apr","modification":"2025-04-04T12:58:21.216Z","creation":"2025-04-04T12:58:21.216Z"},"accession":"S-EPMC11021603","cross_references":{"pubmed":["38303486"],"doi":["10.1002/acn3.52006"]}}